Peter Button

4.0k total citations · 2 hit papers
31 papers, 2.9k citations indexed

About

Peter Button is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Peter Button has authored 31 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Hepatology. Recurrent topics in Peter Button's work include Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers) and Liver Disease Diagnosis and Treatment (5 papers). Peter Button is often cited by papers focused on Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers) and Liver Disease Diagnosis and Treatment (5 papers). Peter Button collaborates with scholars based in Australia, Switzerland and United Kingdom. Peter Button's co-authors include Teerha Piratvisuth, George Lau, Young Kyu Park, Y. Choi, Young‐Woo Kim, Patrick Marcellin, Kyung Hee Lee, Jiafu Ji, Sung Hoon Noh and Hyun Cheol Chung and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Peter Button

29 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

2012 1.2k citations Yung‐Jue Bang, Young‐Woo Kim et al. The Lancet profile →
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

2004 847 citations Patrick Marcellin, George Lau et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Button Australia	15	1.4k	1.2k	1.1k	663	590	31	2.9k
Kuhn Uk Lee South Korea	37	1.3k 1.0×	730 0.6×	1.3k 1.2×	1.0k 1.5×	453 0.8×	99	3.4k
Géraldine Sergent France	20	598 0.4×	830 0.7×	1.7k 1.5×	325 0.5×	127 0.2×	42	2.5k
Eran Sadot Israel	25	833 0.6×	516 0.4×	547 0.5×	1.8k 2.7×	140 0.2×	70	2.8k
Ana Gleisner United States	26	1.1k 0.8×	633 0.5×	1.0k 0.9×	2.1k 3.1×	82 0.1×	111	3.0k
Yu Takahashi Japan	31	1.9k 1.4×	541 0.5×	878 0.8×	2.4k 3.6×	166 0.3×	216	3.7k
Dominik Bettinger Germany	22	262 0.2×	736 0.6×	1.1k 1.0×	262 0.4×	174 0.3×	93	1.6k
Hervé Perrier France	18	504 0.4×	352 0.3×	377 0.3×	627 0.9×	118 0.2×	63	1.3k
Jean–Marc Phelip France	31	605 0.4×	1.2k 1.1×	264 0.2×	1.3k 2.0×	111 0.2×	141	3.2k
Spiros Hiotis United States	20	444 0.3×	488 0.4×	749 0.7×	713 1.1×	83 0.1×	62	1.8k
Hiroyuki Maguchi Japan	35	2.2k 1.6×	867 0.7×	495 0.4×	2.9k 4.4×	159 0.3×	155	4.5k

Countries citing papers authored by Peter Button

Since Specialization

Citations

This map shows the geographic impact of Peter Button's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Button with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Button more than expected).

Fields of papers citing papers by Peter Button

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Button. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Button. The network helps show where Peter Button may publish in the future.

Co-authorship network of co-authors of Peter Button

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Button. A scholar is included among the top collaborators of Peter Button based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Button. Peter Button is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bennell, Kim L., Harrison J Hansford, James H. McAuley, et al.. (2025). The smallest worthwhile effects of strengthening exercise on pain intensity for people with knee osteoarthritis: A benefit-harm trade-off study. Osteoarthritis and Cartilage.

Heery, Graham P., Carolyn A. Luscombe, G R Kinghorn, et al.. (2022). Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial. Scientific Reports. 12(1). 10210–10210. 12 indexed citations

Byrne, David J., Peter Button, Sunil R. Lakhani, et al.. (2020). 297P SP142 immunohistochemistry (IHC) PD-L1 inter- and intra-pathologist agreement in triple negative breast carcinoma (TNBC). Annals of Oncology. 31. S361–S361. 1 indexed citations

Haraoui, Boulos, Gustavo Casado, László Czirják, et al.. (2019). Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies. Rheumatology and Therapy. 6(2). 231–243. 8 indexed citations

Youssef, Peter, Peter Button, Matt Truman, et al.. (2019). Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. The Journal of Rheumatology. 47(8). 1174–1181. 11 indexed citations

Wu, Yi‐Long, Victor Lee, Chong Kin Liam, et al.. (2018). Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 126. 1–8. 35 indexed citations

Mustacchi, Giorgio, José Bines, Emilio Alba, et al.. (2017). Abstract P5-15-06: Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research. 77(4_Supplement). P5–15. 1 indexed citations

Montemurro, Filippo, Peter Ellis, Suzette Delaloge, et al.. (2017). Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study. Cancer Research. 77(4_Supplement). P1–12. 19 indexed citations

Kitson, Matthew T., Stuart K. Roberts, John Colman, et al.. (2015). Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scandinavian Journal of Gastroenterology. 50(4). 462–469. 42 indexed citations

10.

Jones, Graeme, Paul Bird, Geoffrey Littlejohn, et al.. (2015). THU0146 Dispensing of Biologics Prescribed for the Treatment of Rheumatoid Arthritis in the Australian Population. Annals of the Rheumatic Diseases. 74. 246–247. 1 indexed citations

11.

Park, Keunchil, Chong‐Jen Yu, Sang-We Kim, et al.. (2015). First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer. JAMA Oncology. 2(3). 305–305. 173 indexed citations

12.

Kitson, Matthew T., Jacob George, Gregory J. Dore, et al.. (2014). Interleukin‐28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology. 29(7). 1458–1462. 4 indexed citations

13.

Kitson, Matthew T., Gregory J. Dore, Jacob George, et al.. (2012). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology. 58(3). 467–472. 63 indexed citations

14.

Bang, Yung‐Jue, Young‐Woo Kim, Han‐Kwang Yang, et al.. (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet. 379(9813). 315–321. 1248 indexed citations breakdown →

15.

Bilous, Michael, Adrienne Morey, Jane E. Armes, et al.. (2012). Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Research and Treatment. 134(2). 617–624. 28 indexed citations

16.

Hsu, Chiun, Tsung‐Ming Yang, Wu‐Chou Su, et al.. (2009). A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): An interim safety report. Journal of Clinical Oncology. 27(15_suppl). 4585–4585. 6 indexed citations

17.

Buster, Erik H.C.J., Bettina E. Hansen, George Lau, et al.. (2008). PREDICTION OF RESPONSE TO PEGINTERFERON-ALFA IN HBEAG POSITIVE CHRONIC HEPATITIS B: A MODEL BASED ON 721 PATIENTS. Data Archiving and Networked Services (DANS).

18.

Fried, Michael, Teerha Piratvisuth, George Lau, et al.. (2008). HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 47(2). 428–434. 180 indexed citations

19.

Piratvisuth, Teerha, Patrick Marcellin, Graham Cooksley, et al.. (2006). 49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB). Journal of Hepatology. 44. S23–S23. 4 indexed citations

20.

Marcellin, Patrick, George Lau, Ferruccio Bonino, et al.. (2004). Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine. 351(12). 1206–1217. 847 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact